PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
United Therapeutics Corporation (UTHR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US91307C1027

CUSIP

91307C102

Sector

Healthcare

IPO Date

Jun 17, 1999

Highlights

Market Cap

$16.95B

EPS (TTM)

$22.74

PE Ratio

16.70

PEG Ratio

1.61

Total Revenue (TTM)

$2.76B

Gross Profit (TTM)

$2.45B

EBITDA (TTM)

$1.51B

Year Range

$208.62 - $417.82

Target Price

$393.74

Short %

6.14%

Short Ratio

5.67

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
UTHR vs. CTLT UTHR vs. SPY UTHR vs. COST UTHR vs. MID UTHR vs. VDE UTHR vs. NBIX UTHR vs. SCHG UTHR vs. BBH UTHR vs. SRPT UTHR vs. WELL
Popular comparisons:
UTHR vs. CTLT UTHR vs. SPY UTHR vs. COST UTHR vs. MID UTHR vs. VDE UTHR vs. NBIX UTHR vs. SCHG UTHR vs. BBH UTHR vs. SRPT UTHR vs. WELL

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in United Therapeutics Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
14.18%
8.53%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Returns By Period

United Therapeutics Corporation had a return of 64.10% year-to-date (YTD) and 60.02% in the last 12 months. Over the past 10 years, United Therapeutics Corporation had an annualized return of 10.45%, while the S&P 500 had an annualized return of 11.06%, indicating that United Therapeutics Corporation did not perform as well as the benchmark.


UTHR

YTD

64.10%

1M

0.04%

6M

16.79%

1Y

60.02%

5Y*

31.96%

10Y*

10.45%

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of UTHR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-2.32%5.06%1.81%2.01%17.41%15.78%-1.65%16.04%-1.43%4.36%-0.93%64.10%
2023-5.37%-6.51%-8.97%2.75%-8.86%5.25%9.95%-7.56%0.67%-1.33%7.69%-8.38%-20.93%
2022-6.58%-17.67%7.95%-1.03%29.73%2.30%-1.94%-1.93%-7.61%10.10%21.41%-0.64%28.70%
20217.93%2.05%0.05%20.50%-7.77%-3.49%1.40%18.11%-14.10%3.35%-0.66%14.03%42.35%
202010.89%5.42%-7.90%15.54%7.66%2.59%-7.88%-4.05%-5.57%32.90%-1.18%14.44%72.33%
20195.90%9.50%-7.06%-12.61%-18.13%-7.04%1.51%4.19%-3.40%12.65%2.69%-4.53%-19.12%
2018-12.81%-10.19%-3.01%-2.00%-3.21%6.16%8.63%0.07%3.98%-13.31%6.53%-7.79%-26.39%
201714.08%-9.72%-8.35%-7.15%-3.83%7.31%-1.03%1.87%-10.41%1.19%9.61%13.82%3.15%
2016-21.35%-1.01%-8.62%-5.59%13.18%-11.04%14.25%1.05%-3.43%1.69%4.61%14.19%-8.42%
20158.99%9.86%11.21%-7.39%15.05%-5.32%-2.64%-11.07%-12.87%11.73%4.09%2.61%20.94%
2014-9.25%-1.17%-7.29%6.36%-4.27%-7.57%2.77%29.57%9.18%1.80%1.22%-2.32%14.51%
20130.88%10.99%1.77%9.71%-0.43%-1.01%13.84%-5.37%11.20%12.26%4.28%22.50%111.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 93, UTHR is among the top 7% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of UTHR is 9393
Overall Rank
The Sharpe Ratio Rank of UTHR is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of UTHR is 9191
Sortino Ratio Rank
The Omega Ratio Rank of UTHR is 9191
Omega Ratio Rank
The Calmar Ratio Rank of UTHR is 9393
Calmar Ratio Rank
The Martin Ratio Rank of UTHR is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for UTHR, currently valued at 2.12, compared to the broader market-4.00-2.000.002.002.122.10
The chart of Sortino ratio for UTHR, currently valued at 2.80, compared to the broader market-4.00-2.000.002.004.002.802.80
The chart of Omega ratio for UTHR, currently valued at 1.39, compared to the broader market0.501.001.502.001.391.39
The chart of Calmar ratio for UTHR, currently valued at 2.42, compared to the broader market0.002.004.006.002.423.09
The chart of Martin ratio for UTHR, currently valued at 12.26, compared to the broader market-5.000.005.0010.0015.0020.0025.0012.2613.49
UTHR
^GSPC

The current United Therapeutics Corporation Sharpe ratio is 2.12. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of United Therapeutics Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50JulyAugustSeptemberOctoberNovemberDecember
2.12
2.10
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


United Therapeutics Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-12.00%-10.00%-8.00%-6.00%-4.00%-2.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-11.99%
-2.62%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the United Therapeutics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the United Therapeutics Corporation was 93.18%, occurring on Dec 10, 2001. Recovery took 2282 trading sessions.

The current United Therapeutics Corporation drawdown is 11.99%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.18%Jul 13, 2000352Dec 10, 20012282Jan 3, 20112634
-60.3%Apr 24, 20151068Jul 22, 2019428Apr 1, 20211496
-60.2%Feb 28, 200036Apr 17, 200051Jun 29, 200087
-47.37%Apr 28, 2011110Oct 3, 2011451Jul 22, 2013561
-26.83%Dec 12, 2022116May 30, 2023261Jun 12, 2024377

Volatility

Volatility Chart

The current United Therapeutics Corporation volatility is 8.49%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%JulyAugustSeptemberOctoberNovemberDecember
8.49%
3.79%
UTHR (United Therapeutics Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of United Therapeutics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of United Therapeutics Corporation compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.016.7
The chart displays the price to earnings (P/E) ratio for UTHR in comparison to other companies of the Biotechnology industry. Currently, UTHR has a PE value of 16.7. This PE ratio falls in the average range for the industry.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.01.6
The chart displays the price to earnings to growth (PEG) ratio for UTHR in comparison to other companies of the Biotechnology industry. Currently, UTHR has a PEG value of 1.6. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for United Therapeutics Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab